Bleselumab (ASKP 1240) 是一种人抗-CD40 单克隆抗体 (mAb)。Bleselumab 以高亲和力结合人 CD40 (Kd: 0.24 nM)。Bleselumab 通过阻断 CD40 与其配体 CD40L 的相互作用来抑制免疫反应。Bleselumab 可预防器官移植排斥反应。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-TNFRSF5 / CD40 Reference Antibody (bleselumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-TNFRSF5 / CD40 Reference Antibody (bleselumab) is 99.21%, determined by SEC-HPLC.

Immobilized human TNFRSF5 / CD40 His at 2 ug/mL can bind Anti-TNFRSF5 / CD40 Reference Antibody (bleselumab), EC50=0.0252 ug/mL.

Human CD40 CHO cells were stained with Anti-TNFRSF5 / CD40 Reference Antibody (bleselumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.6311 ug/mL.

Anti-TNFRSF5 / CD40 Reference Antibody (bleselumab) FACS Blocking was evaluated using CCRF-CEM. The IC50 was approximately 1.359 ug/mL.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.